Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024
Details of the presentation are as follows:
Title: |
Advancing Bacteriophage Therapy from Discovery to Clinical Trials |
|
|
Session: |
Phage Therapy Session 2 – Clinical Application |
|
|
Presenter: |
|
|
|
Day: |
|
|
|
Time: |
11:20am-11:40am AEST ( |
|
|
For more information: https://www.vom2024.org/ |
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
At Armata:
ir@armatapharma.com
310-665-2928
Investor Relations:
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-presentation-at-viruses-of-microbes-2024-302191113.html
SOURCE